Philadelphia, Pa. (January 13, 2011) – Nearly half of children who survive an episode of bacterial meningitis experience persistent behavioral, intellectual, or other complications, reports a study in the January issue of The Pediatric Infectious Disease Journal®. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health, a leading provider of information and business intelligence for students, professionals, and institutions in medicine, nursing, allied health, and pharmacy.
“While neurologic deficits may resolve over time, subtle behavioral deficits may not be appreciated initially and may continue to affect survivors for many years,” according to the new study, led by Dr. Aruna Chandran of Johns Hopkins University, Baltimore.
Findings May Add to Arguments for Vaccinations to Prevent Meningitis
Through a comprehensive review of published studies, the researchers identified 1,433 patients who were survivors of childhood bacterial meningitis. The analysis focused on the rates and types of long-term complications-the children in the studies were followed up for at least five years, and in some cases more than 20 years.
Key to Dr. Guralnick’s work is the DSA, which he proposed in 2001, which provides an integrated perspective on the needs of children facing developmental delays. In this perspective, the focus is on scientific understanding of how children develop-and the family’s critical role in supporting that development. The DSA is thoroughly integrated with the latest work in developmental science.
Overall, 49.2 percent of the children have at least one type of long-term complication. Nearly 80 percent of the complications were classified as behavioral and/or intellectual deficits-most commonly low IQ or “cognitive impairment.” Other problems in this category included behavioral problems and attention deficit hyperactivity disorder.
Most of the remaining 20 percent of complications were major neurological abnormalities and hearing impairments. There were some differences in types of long-term complications among children with different bacterial causes of meningitis. However, the specific causative bacteria were confirmed in just over one-fourth of the children studied.
“For early intervention practices to be comprehensive, it is essential to address as many risk factors as possible at the level of family patterns of interaction resulting from stressors created at the level of child development or due to limited family resources,” Dr. Guralnick writes. He believes that the DSA meets the need for an integrated perspective focusing on the critical factors influencing the child’s development, and the family’s ability to support it.
Bacterial meningitis is a potentially fatal infection of the tissues lining the brain and spinal cord. In recent years, vaccines protecting against bacteria that commonly cause meningitis have led to significant reductions in the rates of childhood meningitis, although with a shift to different types of causative bacteria.
Previous studies have reported on various types of complications in survivors of childhood meningitis. However, most have included relatively short follow-up periods or focused on one specific type of complication.
The new results provide a more complete picture of the rates and types of long-term complications in childhood survivors of bacterial meningitis. Approximately 50 percent of these children have some type of complication, most commonly related to academic performance or behavioral problems.
Previous studies have found that at least some of the obvious neurological abnormalities seen after childhood meningitis will resolve within a few years. “In contrast” Dr. Chandran and co-authors write, “subtle neurologic deficits, such as impaired school performance, behavioral problems, and attention deficit disorder, may not be appreciated initially and may continue to affect survivors for many years.”
Further research will be needed to provide a more complete picture of the types and rates of long-term complications among children who survive meningitis.
Meanwhile, Dr. Chandran and co-authors believe that the full impact of these long-term complications should be an important consideration in making recommendations for the use of vaccines against common bacterial causes of meningitis.
About Pediatric Infectious Disease Journal®
The Pediatric Infectious Disease Journal® (www.pidj.com) is a peer-reviewed, multidisciplinary journal directed to physicians and other health care professionals who manage infectious diseases of childhood. The journal delivers the latest insights on all aspects of infectious disease in children, from state-of-art diagnostic techniques to the most effective drug therapies and other essential treatment protocols. The Pediatric Infectious Disease Journal is official journal of the Pediatric Infectious Diseases Society and the European Society for Paediatric Infectious Diseases.
About Lippincott Williams & Wilkins
Lippincott Williams & Wilkins (LWW) is a leading international publisher for healthcare professionals and students with nearly 300 periodicals and 1,500 books in more than 100 disciplines publishing under the LWW brand, as well as content-based sites and online corporate and customer services. LWW is part of Wolters Kluwer Health , a leading provider of information and business intelligence for students, professionals and institutions in medicine, nursing, allied health, pharmacy and the pharmaceutical industry.
Wolters Kluwer Health is a division of Wolters Kluwer, a leading global information services and publishing company. The company provides products and services for professionals in the health, tax, accounting, corporate, financial services, legal, and regulatory sectors. Wolters Kluwer had 2008 annual revenues of €3.4 billion ($4.9 billion), employs approximately 20,000 people worldwide, and maintains operations in over 35 countries across Europe, North America, Asia Pacific, and Latin America. Wolters Kluwer is headquartered in Amsterdam, the Netherlands. Its shares are quoted on Euronext Amsterdam (WKL) and are included in the AEX and Euronext 100 indices. Visit www.wolterskluwer.com for information about our market positions, customers, brands, and organization.
Contacts:
Robert Dekker
Director of Communications
Wolters Kluwer Health
+1 (215) 521-8928
Robert.Dekker@wolterskluwer.com
Connie Hughes
Director, Marketing Communications
Wolters Kluwer Health Medical Research
+1 (646) 674-6348
Connie.Hughes@wolterskluwer.com